Also known as: second-generation antipsychotics, Second-Generation Antipsychotics
Newron Pharmaceuticals has had a constructive FDA meeting about the clinical hold on its evenamide Phase III ENIGMA-TRS 2 trial and also secured up to €38 million in funding to advance the program. The company plans to propose changes to address the FDA’s concerns, while the financing extends its cash runway beyond key 12-week results.
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone), an atypical antipsychotic for schizophrenia and manic or mixed episodes in bipolar I disorder. The drug will be available by the third quarter of 2026.
